Pomalidomide is under clinical development by Qilu Pharmaceutical and currently in Phase III for Refractory Multiple Myeloma. According to GlobalData, Phase III drugs for Refractory Multiple Myeloma have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Pomalidomide’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Pomalidomide overview

Pomalidomide is under development for the treatment of relapsed and refractory multiple myeloma. It is administered through oral route as capsule formulation. It acts by targeting protein cereblon (CRBN).

Qilu Pharmaceutical overview

Qilu Pharmaceutical (Qilu) develops, manufactures and markets generic drugs and active pharmaceutical ingredients (API’s). It offers products for various therapies such as oncology, cerebrovascular and cardiovascular diseases, infectious diseases, psychological and neurological diseases, respiratory system and eye diseases. The company’s generic drugs include lyophilized powder for injection, powder for injection, small volume parenteral solution, tablets, capsules, granules, ophthalmic solutions, creams, ointments, inhalers and spray; and synthesized, lyophilized, sterile crystallized and fermented APIs. Qilu operates manufacturing facilities with various certifications of US FDA, European Medicines Agency (EMA), PMDA of Japan, Medicines and Healthcare products Regulatory Agency (MHRA) of UK, Therapeutic Goods Administration (TGA) of Australia and other national regulatory authorities. The company markets products across North and South America, Europe, Asia Pacific, and the Middle East and Africa. Qilu is headquartered in Jinan, Shandong, China.

For a complete picture of Pomalidomide’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.